• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Derrick Sung Joins Aerin Medical as Chief Financial Officer

    11/20/23 9:00:00 AM ET
    $IRTC
    $LUNG
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email

    A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry

    Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/

    Derrick Sung has been appointed chief financial officer of Aerin Medical. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation where he scaled the finance organization and led the company through significant growth and a successful IPO. (Photo: Business Wire)

    Derrick Sung has been appointed chief financial officer of Aerin Medical. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation where he scaled the finance organization and led the company through significant growth and a successful IPO. (Photo: Business Wire)

    "It is with great pleasure that we welcome Derrick as the latest addition to our leadership team," said Matt Brokaw, CEO of Aerin Medical. "With a proven track record of financial leadership and a wealth of operating expertise, Derrick will play a pivotal role in accelerating our pursuit of a new standard of care for millions of untreated sufferers of ENT conditions."

    Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation (NASDAQ:LUNG) where he scaled the finance organization and led the company through significant growth and a successful IPO. Before that, he led strategy and corporate development at iRhythm Technologies (NASDAQ:IRTC). Previously, Sung spent seven years on Wall Street as a senior equity research analyst covering the medical devices sector, directed marketing and business development for Boston Scientific's Neuromodulation division, led management consulting engagements at the Boston Consulting Group, and designed heart catheters as an R&D engineer for Guidant Corporation. He received his Ph.D. in bioengineering from the University of California, San Diego, his Master of Business Administration from San Diego State University, and his Bachelor of Science degree in mechanical engineering from Stanford University.

    "I am excited to join the exceptional team at Aerin Medical as we embark on the next phase of growth," said Sung. "Fueled by compelling fundamentals and a rare financial profile, we are poised to achieve remarkable success."

    About Aerin Medical

    Aerin Medical is a privately held, venture-backed company, with U.S. offices in California and Texas. Aerin's mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company's products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, leverage Aerin's proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients' symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 100,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231120576987/en/

    Get the next $IRTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRTC
    $LUNG

    CompanyDatePrice TargetRatingAnalyst
    iRhythm Holdings Inc.
    $IRTC
    1/5/2026$210.00In-line → Outperform
    Evercore ISI
    iRhythm Holdings Inc.
    $IRTC
    9/23/2025$185.00In-line
    Evercore ISI
    iRhythm Holdings Inc.
    $IRTC
    8/20/2025$200.00Buy
    BofA Securities
    Pulmonx Corporation
    $LUNG
    7/31/2025$2.50Overweight → Neutral
    Piper Sandler
    iRhythm Holdings Inc.
    $IRTC
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    Pulmonx Corporation
    $LUNG
    3/10/2025$17.00Buy
    D. Boral Capital
    Pulmonx Corporation
    $LUNG
    12/11/2024$17.00 → $7.50Buy → Neutral
    Citigroup
    iRhythm Holdings Inc.
    $IRTC
    12/3/2024$86.00Equal Weight
    Wells Fargo
    More analyst ratings

    $IRTC
    $LUNG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    iRhythm upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded iRhythm from In-line to Outperform and set a new price target of $210.00

    1/5/26 8:34:48 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on iRhythm with a new price target

    Evercore ISI initiated coverage of iRhythm with a rating of In-line and set a new price target of $185.00

    9/23/25 8:17:27 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    BofA Securities initiated coverage on iRhythm with a new price target

    BofA Securities initiated coverage of iRhythm with a rating of Buy and set a new price target of $200.00

    8/20/25 8:56:18 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) (the "Company" or "Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the "Grant Date"), Pulmonx granted equity awards under its 2025 Inducement Plan (the "Inducement Plan") to 17 individuals hired by Pulmonx in the first two quarters of 2026. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of t

    6/1/26 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm Holdings to Participate in Upcoming Investor Conferences

    SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that the company will be participating in the following investor conferences. William Blair 46th Annual Growth Stock Conference on June 2, 2026, at 8:00 a.m. CT (6:00 a.m. PT)Truist Securities MedTech Conference on June 16, 2026, at 2:20 p.m. ET (11:20 a.m. PT) Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Holdings, Inc. i

    5/19/26 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Holdings Announces First Quarter 2026 Financial Results

    SAN FRANCISCO, April 30, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Highlights Revenue of $199.4 million, a 25.7% increase compared to first quarter 2025Gross margin of 70.9%, a 210-basis point increase compared to first quarter 2025Net loss of $13.9 million, a $16.8 million improvement compared to first quarter 2025Adjusted EBITDA and adjusted EBITDA margin of $14.1 million and 7.1%, respectively, a $16.7 million and 880-basis point improvement, r

    4/30/26 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    SEC Filings

    View All

    iRhythm Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - iRhythm Holdings, Inc. (0001388658) (Filer)

    6/5/26 7:47:02 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Pulmonx Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Pulmonx Corp (0001127537) (Filer)

    6/4/26 4:04:20 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - iRhythm Holdings, Inc. (0001388658) (Filer)

    5/28/26 7:33:42 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Talwalkar Abhijit Y bought $56,892 worth of shares (5,312 units at $10.71) and sold $626,430 worth of shares (5,312 units at $117.93) as part of a pre-agreed trading plan (SEC Form 4)

    4 - iRhythm Holdings, Inc. (0001388658) (Issuer)

    5/12/26 5:12:08 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Director Florin Daniel P bought $71,362 worth of shares (23,321 units at $3.06), increasing direct ownership by 25% to 117,231 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    6/5/25 8:39:08 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/5/24 11:59:44 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Science &Techn. Officer Radhakrishnan Srikanth sold $22,325 worth of shares (14,497 units at $1.54), decreasing direct ownership by 4% to 331,239 units (SEC Form 4) to cover withholding tax

    4 - Pulmonx Corp (0001127537) (Issuer)

    6/3/26 4:18:16 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    GENERAL COUNSEL Lehman David Aaron sold $22,475 worth of shares (14,594 units at $1.54), decreasing direct ownership by 4% to 376,161 units (SEC Form 4) (withholding obligation)

    4 - Pulmonx Corp (0001127537) (Issuer)

    6/3/26 4:17:29 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    CHIEF COMMERCIAL OFFICER Rose Geoffrey Beran sold $12,355 worth of shares (8,023 units at $1.54), decreasing direct ownership by 2% to 457,711 units (SEC Form 4) (for withholding tax)

    4 - Pulmonx Corp (0001127537) (Issuer)

    6/3/26 4:16:42 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/14/24 7:47:49 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 12:54:21 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/12/24 10:34:16 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Leadership Updates

    Live Leadership Updates

    View All

    iRhythm Holdings Appoints Jason Patten to its Board of Directors

    SAN FRANCISCO, March 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, is pleased to announce the appointment of Jason Patten to its Board of Directors, effective March 12, 2026. Mr. Patten brings decades of strategic leadership in healthcare, reinforcing iRhythm's commitment to innovation, operational excellence, and long-term growth. "We are thrilled to welcome Jason Patten to our Board of Directors at an important moment in iRhythm's evolution," said Abhi Talwalkar, Chairman of the Board of Directors. "As we scale and expand profitability, we are focus

    3/12/26 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

    REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him

    4/2/24 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

    iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

    2/29/24 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Financials

    Live finance-specific insights

    View All

    iRhythm Holdings Announces First Quarter 2026 Financial Results

    SAN FRANCISCO, April 30, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Highlights Revenue of $199.4 million, a 25.7% increase compared to first quarter 2025Gross margin of 70.9%, a 210-basis point increase compared to first quarter 2025Net loss of $13.9 million, a $16.8 million improvement compared to first quarter 2025Adjusted EBITDA and adjusted EBITDA margin of $14.1 million and 7.1%, respectively, a $16.7 million and 880-basis point improvement, r

    4/30/26 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Pulmonx Reports First Quarter 2026 Financial Results

    REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026. Recent Highlights Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basisDelivered $13.3 million in U.S. revenue in the first quarter of 2025, representing a 7% year-over-year decreaseDelivered $7.3 million in international revenue in the first quarter of 2026, representing a 12% year-over-year decrease

    4/29/26 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm Holdings to Report First Quarter 2026 Financial Results on April 30, 2026

    SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2026 after the close of trading on Thursday, April 30, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Holdings, Inc. iRhythm is a leading digital

    4/16/26 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care